News
CGEM
23.17
-2.69%
-0.64
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
TipRanks · 1d ago
Cullinan Therapeutics Files For Resale Of Up To 14.4M Shares By The Selling Stockholders
Benzinga · 1d ago
Cullinan Therapeutics files to sell 14.4M shares of common stock for holders
Healthcare Cullinan Therapeutics files to sell shares of common stock for holders May 16, 2024 4:42 PM ETCullinanTherapeutics, Inc. (CGEM) Stock. The company filed a prospectus related to the offer and sale of up to the shares.
Seeking Alpha · 1d ago
CULLINAN THERAPEUTICS INC FILES FOR RESALE OF UP TO 14.4 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 1d ago
Cullinan Oncology Price Target Cut to $28.00/Share From $29.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Lowers Price Target to $28
Benzinga · 1d ago
Cullinan Oncology reports Q1 results
Ullinan Oncology reports Q1 results. Expects cash resources to provide runway into 2028 based on its current operating plan. Cullinan Therapeutics, Inc. (CGEM) stock down 2.7% in pre-market trading on Tuesday.
Seeking Alpha · 1d ago
Buy Rating Affirmed for Cullinan Management Ahead of Key ASCO Presentation and Strong Financials
TipRanks · 1d ago
Cullinan Oncology Price Target Maintained With a $36.00/Share by Wedbush
Dow Jones · 1d ago
Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Benzinga · 1d ago
Cullinan Management (CGEM) Gets a Buy from Wedbush
TipRanks · 1d ago
Stifel Nicolaus Remains a Buy on Cullinan Management (CGEM)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)
TipRanks · 1d ago
CULLINAN THERAPEUTICS, INC. <CGEM.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $28 FROM $29
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Wall Street securities analysts revise their ratings and price targets on several companies. AN2 Therapeutics, Ecolab and RPM International among companies with revised ratings. Analysts raise target prices for AN2, RPM International, Airbnb, Cisco, Analog Devices.
Reuters · 1d ago
Buy Rating on Cullinan Management: Promising Pipeline and Strategic Pivot to Autoimmunity
TipRanks · 1d ago
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
Investorplace · 2d ago
Cullinan Therapeutics, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 2d ago
Cullinan Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Cullinan Therapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 86 cents per share; analysts expected a loss of 99 cents. The average analyst rating on the shares is "strong buy" for the company.
Reuters · 2d ago
More
Webull provides a variety of real-time CGEM stock news. You can receive the latest news about Cullinan Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CGEM
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.